Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

Last updated: May 20, 2025
Sponsor: Intergroupe Francophone du Myelome
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Multiple Myeloma

Leukemia

Bone Neoplasm

Treatment

N/A

Clinical Study ID

NCT06062537
IFM 2023-01
  • Ages > 18
  • All Genders

Study Summary

200 adult patients with multiple myeloma receiving teclistamb will be included. Effectiveness, safety, and condition of use of teclistamab in early access program (post-MA) will be assessed. Primary objective is the evaluation of overall response rate (ORR) of teclistamab according to IMWG criteria.

This is a multicenter, prospective, observational study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult patient (≥18 years) with multiple myeloma who will receive at least one doseof teclistamab (first dose of the step-up dose)

Exclusion

Exclusion Criteria:

  • Patients alive at the start of the study who did not receive study information orwho objected to the collection of data

  • Patients who received teclistamab as part of an interventional clinical trial

  • Patients who are initiating teclistamab as part of a current interventional clinicaltrial

Study Design

Total Participants: 200
Study Start date:
September 19, 2023
Estimated Completion Date:
September 30, 2026

Connect with a study center

  • CHU Amiens Picardie

    Amiens,
    France

    Site Not Available

  • CH d'ANNECY

    Annecy,
    France

    Site Not Available

  • Centre hospitalier d'Argenteuil

    Argenteuil,
    France

    Site Not Available

  • Hopital de la cote Basque

    Bayonne,
    France

    Site Not Available

  • CHU de Besançon

    Besançon,
    France

    Site Not Available

  • CHU Bordeaux

    Bordeaux, 31400
    France

    Site Not Available

  • Centre hospitalier de Brive-la-Gaillarde

    Brive-la-Gaillarde,
    France

    Site Not Available

  • CHU CAEN

    Caen,
    France

    Site Not Available

  • Centre hospitalier Métropole de Savoie

    Chambéry,
    France

    Site Not Available

  • CHU Clermont-Ferrand Site Estaing

    Clermont Ferrand,
    France

    Site Not Available

  • CHU Henri Mondor

    Créteil,
    France

    Site Not Available

  • Chu Dijon

    Dijon,
    France

    Site Not Available

  • CH Dunkerque

    Dunkerque,
    France

    Site Not Available

  • CHU de Lille

    Lille,
    France

    Site Not Available

  • Groupe hospitalier Bretagne Sud

    Lorient,
    France

    Site Not Available

  • CHU de Lyon

    Lyon,
    France

    Site Not Available

  • Institut Paoli Calmette

    Marseille,
    France

    Site Not Available

  • CH de METZ

    Metz,
    France

    Site Not Available

  • CHU Saint-Eloi - CHU de Montpellier

    Montpellier,
    France

    Site Not Available

  • Chu de Nantes

    Nantes,
    France

    Site Not Available

  • CHU de Nice

    Nice,
    France

    Site Not Available

  • Hopital Necker

    Paris,
    France

    Site Not Available

  • Hopital saint louis

    Paris,
    France

    Site Not Available

  • CH Perpignan

    Perpignan,
    France

    Site Not Available

  • Hopital Novo

    Pontoise,
    France

    Site Not Available

  • Chu de Rennes

    Rennes,
    France

    Site Not Available

  • Centre Henri Becquerel

    Rouen,
    France

    Site Not Available

  • Institut de Cancérologie Lucien Neuwirth, CHU Saint-Etienne

    Saint Priest-en-Jarez,
    France

    Site Not Available

  • Institut de Cancérologie Strasbourg Europe

    Strasbourg,
    France

    Site Not Available

  • CHU Toulouse

    Toulouse,
    France

    Site Not Available

  • CHU de Tours

    Tours,
    France

    Site Not Available

  • CH Bretagne Atlantique

    Vannes,
    France

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.